目次

1. Introduction to BCR-ABL Inhibitors
1.1 Overview
1.2 Mechanism of Action of BCR-ABL Inhibitors
1.3 Role of BCR-ABL Inhibitor in Cancer

2. Global BCR-ABL Inhibitor Drug Market Insight
2.1 Current Market Scenario
2.2 Future Market Opportunity

3. BCR-ABL Inhibitor Drug Market Regional Analysis
3.1 US
3.2 Europe
3.3 Japan
3.4 Rest of World

4. BCR-ABL Inhibitor Drug Market by Product
4.1 First Generation BCR-ABL Inhibitor
4.2 Second Generation BCR-ABL Inhibitor
4.3 Third Generation BCR-ABL Inhibitor

5. Imatinib - 1st Generation BCR-ABL Inhibitor
5.1 Overview
5.2 Patent and Exclusivity
5.3 Pricing and Dosage Analysis
5.3.1 Branded
5.3.2 Generic
5.4 Sales Analysis

6. Dasatinib - 2nd Generation BCR-ABL Inhibitor
6.1 Overview
6.2 Patent and Exclusivity
6.3 Pricing and Dosage Analysis
6.3.1 Branded
6.3.2 Generic
6.4 Sales Analysis

7. Nilotinib - 2nd Generation BCR-ABL Inhibitor
7.1 Overview
7.2 Patent and Exclusivity
7.3 Price and Dosage Analysis
7.4 Sales Analysis

8. Bosutinib - 2nd Generation BCR-ABL Inhibitor
8.1 Overview
8.2 Patent and Exclusivity
8.3 Pricing and Dosage Analysis
8.4 Sales Analysis

9. Ponatinib - 3rd Generation BCR-ABL Inhibitor
9.1 Overview
9.2 Patent and Exclusivity
9.3 Pricing and Dosage Analysis
9.4 Sales Analysis

10. Asciminib - 3rd Generation BCR-ABL Inhibitor
10.1 Overview
10.2 Patent and Exclusivity
10.3 Pricing and Dosage Analysis
10.4 Sales Analysis

11. Olverembatinib - 3rd Generation BCR-ABL Inhibitor
11.1 Overview and Patent Analysis
11.2 Sales Analysis

12. BCR-ABL Inhibitor Market Clinical Trial Insights
12.1 By Indication
12.2 By Company
12.3 By Country
12.4 By Patient Segment
12.5 By Phase

13. Global Bcr Abl Tyrosine Kinase Inhibitors Drugs Clinical Trials By Company, Indication and Phase
13.1 Preclinical
13.2 Phase-I
13.3 Phase-I/II
13.4 Phase-II
13.5 Phase-II/III
13.6 Phase-III
13.7 Preregistration
13.8 Registered

14. Marketed Bcr Abl Tyrosine Kinase Inhibitors Drugs Clinical Insight Company and Indication

15. BCR-ABL Inhibitors Market Dynamics
15.1 Market Favorable Parameters
15.2 Market Challenges

16. Competitive Landscape
16.1 1St Biotherapeutics
16.2 Aerovate Therapeutics
16.3 Ascentage Pharma
16.4 AtlasMedx
16.5 Bayer HealthCare
16.6 BenevolentAI
16.7 CSPC Ouyi Pharmaceutical
16.8 Deciphera Pharmaceuticals
16.9 Exvastat
16.10 Fusion Pharma
16.11 Georgetown University
16.12 Guangzhou Institutes of Biomedicine and Health
16.13 Il-Yang
16.14 Inhibikase Therapeutics
16.15 Jiangsu Hansoh Pharmaceutical
16.16 Novartis
16.17 Novartis Pharmaceuticals Corporation
16.18 Pfizer
16.19 Pharm-Sintez
16.20 Shenzhen TargetRx
16.21 Sun Pharma Advanced Research Company
16.22 Takeda
16.23 Terns Pharmaceuticals
16.24 Theseus Pharmaceuticals
16.25 Vectura
16.26 Xspray Pharma
16.27 YD Global Life Science

List of Figures & Tables
Figure 1-1: Therapeutic Options for Management of CML
Figure 1-2: Evolution of BCR-ABL Inhibitors Development
Figure 1-3: Imatinib - Mechanism of Action in CML
Figure 1-4: Pathways Regulated by BCR-ABL in Cancer
Figure 2-1: Global - Estimated Leukemia Incidences and Death, 2020 and 2025
Figure 2-2: BCR-ABL Inhibitor - Drugs Sales (US$ Million), Q1’2023
Figure 2-3: BCR-ABL Inhibitor - Drugs Sales (%), Q1’2023
Figure 2-4: BCR-ABL Inhibitor - Drugs Sales (US$ Million), 2022
Figure 2-5: BCR-ABL Inhibitor - Drugs Sales (US$ Million), 2021
Figure 2-6: BCR-ABL Inhibitor - Drugs Sales (US$ Million), 2020
Figure 2-7: BCR-ABL Inhibitor - Drugs Sales (US$ Million), 2019
Figure 2-8: Global - BCR-ABL Inhibitors Drugs Market Opportunity (US$ Billion), 2023-2029
Figure 3-1: US - Leukemia Incidences and Death, 2020 and 2025
Figure 3-2: US vs. ROW - BCR-ABL Inhibitor Drugs Market (US$ Billion), 2022
Figure 3-3: US vs. ROW - BCR-ABL Inhibitor Drugs Market (%), 2022
Figure 3-4: US - BCR-ABL Inhibitors Drugs Market Opportunity (US$ Billion), 2023 - 2029
Figure 3-5: Europe - Leukemia Incidences and Death, 2020 and 2025
Figure 3-6: Europe - BCR-ABL Inhibitors Drugs Market Opportunity (US$ Million), 2023 - 2029
Figure 3-7: Japan - Leukemia Incidences and Death, 2020 and 2025
Figure 3-8: Japan - BCR-ABL Inhibitors Drugs Market Opportunity (US$ Million), 2022 - 2028
Figure 3-9: China - Leukemia Incidences and Death, 2020 and 2025
Figure 3-10: India - Leukemia Incidences and Death, 2020 and 2025
Figure 3-11: China - BCR-ABL Inhibitors Drugs Market Opportunity (US$ Million), 2023 - 2029
Figure 4-1: First Generation vs. Others - BCR-ABL Inhibitor Drugs Market (US$ Million), Q1’2023
Figure 4-2: First Generation vs. Others - BCR-ABL Inhibitor Drugs Market (%), Q1’2023
Figure 4-3: First Generation vs. Others - BCR-ABL Inhibitor Drugs Market (US$ Million), 2022
Figure 4-4: First Generation vs. Others - BCR-ABL Inhibitor Drugs Market (%), 2022
Figure 4-5: Second Generation vs. Others - BCR-ABL Inhibitor Drugs Market (US$ Million), Q1’2023
Figure 4-6: Second Generation vs. Others - BCR-ABL Inhibitor Drugs Market (%), Q1’2023
Figure 4-7: Second Generation BCR-ABL Inhibitor Drugs Market by Drug Type (US$ Million), Q1’2023
Figure 4-8: Second Generation BCR-ABL Inhibitor Drugs Market by Drug Type (%), Q1’2023
Figure 4-9: Second Generation vs. Others - BCR-ABL Inhibitor Drugs Market (US$ Million), 2022
Figure 4-10: Second Generation vs. Others - BCR-ABL Inhibitor Drugs Market (%), 2022
Figure 4-11: Second Generation BCR-ABL Inhibitor Drugs Market by Drug Type (US$ Million), 2022
Figure 4-12: Second Generation BCR-ABL Inhibitor Drugs Market by Drug Type (%), 2022
Figure 4-13: Third Generation vs. Others - BCR-ABL Inhibitor Drugs Market (US$ Million), Q1’2023
Figure 4-14: Third Generation vs. Others - BCR-ABL Inhibitor Drugs Market (%), Q1’2023
Figure 4-15: Third Generation vs. Others - BCR-ABL Inhibitor Drugs Market (US$ Million), 2022
Figure 4-16: Third Generation vs. Others - BCR-ABL Inhibitor Drugs Market (%), 2022
Figure 5-1: US - Imatinib FDA Orphan Drug Designation by Indication
Figure 5-2: Imatinib - Approval Year by Region
Figure 5-3: US - Gleevec FDA Approval History by Indication
Figure 5-4: US - Gleevec Patent Approval and Expiration Year
Figure 5-5: Imatinib - Ist Generic Approval by Region
Figure 5-6: US - Cost of Supply of 90 Tablets and Per Unit Cost of Gleevec 100mg (US$), April’2023
Figure 5-7: US - Cost of Supply of 30 Tablets and Per Unit Cost of Gleevec 400mg (US$), April’2023
Figure 5-8: UK - Cost of Supply of 60 Tablets and Per Unit Cost of Glivec 100mg (GBP/US$), April’2023
Figure 5-9: UK - Cost of Supply of 30 Tablets and Per Unit Cost of Glivec 400mg (GBP/US$), April’2023
Figure 5-10: US - Cost of Supply of 30 Tablets and Per Unit Cost of Imatinib 100mg (US$), April’2023
Figure 5-11: US - Cost of Supply of 90 Tablets and Per Unit Cost of Imatinib 100mg (US$), April’2023
Figure 5-12: US - Cost of Supply of 30 Tablets and Per Unit Cost of Imatinib 400mg (US$), April’2023
Figure 5-13: UK - Cost of Supply of 60 Tablets and Per Unit Cost of Imatinib 100mg (GBP/US$), April’2023
Figure 5-14: UK - Cost of Supply of 30 Tablets and Per Unit Cost of Glivec 400mg (GBP/US$), April’2023
Figure 5-15: Imatinib - Recommended Initial Dose in Adult by Therapeutic Condition (mg/day)
Figure 5-16: Global - Gleevec/Glivec Annual Sales (US$ Million), 2019-2023
Figure 5-17: US - Gleevec/Glivec Yearly Sales (US$ Million), 2019-2023
Figure 5-18: ROW - Gleevec/Glivec Yearly Sales (US$ Million), 2019-2023
Figure 5-19: Regional - Gleevec/Glivec Quarterly Sales (US$ Million), Q1’2023
Figure 5-20: Gleevec/Glivec - Annual Sales by Region (%), Q1’2023
Figure 5-21: Global - Gleevec/Glivec Quarterly Sales (US$ Million), 2022
Figure 5-22: Regional - Gleevec/Glivec Quarterly Sales (US$ Million), 2022
Figure 5-23: Gleevec/Glivec - Annual Sales by Region (%), 2022
Figure 6-1: US - Sprycel Orphan Drug Designation Approval and Exclusivity for CML
Figure 6-2: US - Sprycel Orphan Drug Designation Approval and Exclusivity for Ph+ ALL
Figure 6-3: US - Sprycel Orphan Drug Designation and FDA Approval Year
Figure 6-4: Sprycel - Approval Year by Region
Figure 6-5: US - Sprycel Approval Year by Indication
Figure 6-6: US - Sprycel Patent Approval and Expiration Year
Figure 6-7: Japan - Sprycel Approval and Patent Exclusivity Year
Figure 6-8: Europe - Branded and 1st Generic Approval Year
Figure 6-9: US - Cost of Supply of 60 Tablets and Per Unit Cost of Sprycel 20mg (US$), April’2023
Figure 6-10: US - Cost of Supply of 60 Tablets and Per Unit Cost of Sprycel 50mg and 70mg (US$), April’2023
Figure 6-11: US - Cost of Supply of 30 Tablets and Per Unit Cost of Sprycel 80mg, 100mg and 140mg (US$), April’2023
Figure 6-12: UK - Cost of Supply of 60 Tablets and Per Unit Cost of Sprycel 20mg (GBP/US$), April’2023
Figure 6-13: UK - Cost of Supply of 60/30 Tablets and Per Unit Cost of Sprycel 50mg, 80mg, 100mg and 140mg (GBP/US$), April’2023
Figure 6-14: UK - Cost of Supply of 60 Tablets and Per Unit Cost of Dasatinib 20mg (GBP/US$), April’2023
Figure 6-15: UK - Cost of Supply of 30 Tablets and Per Unit Cost of Dasatinib 50mg, 80mg, 100mg and 140mg (GBP/US$), April’2023
Figure 6-16: Dasatinib - Initial Recommended Dose by Indication for Adults (mg/day)
Figure 6-17: Dasatinib - Initial Recommended Dose by Indication for Pediatric Patients by Weight (mg/day)
Figure 6-18: Global - Sprycel Annual Sales (US$ Million), 2019-2023
Figure 6-19: Regional - Sprycel Annual Sales (US$ Million), Q1’2023
Figure 6-20: Regional - Sprycel Annual Sales (%), Q1’2023
Figure 6-21: Regional - Sprycel Annual Sales (US$ Million), 2022
Figure 6-22: Regional - Sprycel Annual Sales (%), 2022
Figure 6-23: Global - Sprycel Quarterly Sales (US$ Million), 2022
Figure 6-24: US - Sprycel Quarterly Sales (US$ Million), 2022
Figure 6-25: ROW - Sprycel Quarterly Sales (US$ Million), 2022
Figure 6-26: US - Sprycel Annual Sales (US$ Million), 2019-2023
Figure 6-27: ROW - Sprycel Annual Sales (US$ Million), 2019-2023
Figure 7-1: US - Tasigna Orphan Drug Designation Approval and Exclusivity for CML
Figure 7-2: Tasigna - Approval Year by Region
Figure 7-3: US - Tasigna Orphan Drug Designation and Approval Year
Figure 7-4: Europe - Tasigna Orphan Drug Designation and Approval Year
Figure 7-5: US - Tasigna Approval History by Indication
Figure 7-6: US - Tasigna Patent Approval and Expiration Year
Figure 7-7: Canada - Tasigna Patent Approval and Expiration Year
Figure 7-8: US - Tasigna FDA Approval and Patent Exclusivity Year
Figure 7-9: Europe - Tasigna EMA Approval and Patent Exclusivity Year
Figure 7-10: US - Cost of Supply of 120 Capsules and Per Unit Cost of Tasigna 50mg (US$), April’2023
Figure 7-11: US - Cost of Supply of 28 Capsules and Per Unit Cost of Tasigna 150mg and 200mg (US$), April’2023
Figure 7-12: US - Cost of Supply of 112 Capsules and Per Unit Cost of Tasigna 1500mg and 200mg (US$), April’2023
Figure 7-13: UK - Cost of Supply of 120 Capsules and Per Unit Cost of Tasigna 50mg (GBP/US$), April’2023
Figure 7-14: UK - Cost of Supply of 112 Capsules and Per Unit Cost of Tasigna 150mg and 200mg (GBP/US$), April’2023
Figure 7-15: Nilotinib - Initial Recommended Dose by Indication (mg/day)
Figure 7-16: Nilotinib - Minimum and Maximum Recommended Dose in Pediatric CML (mg/day)
Figure 7-17: Global - Tasigna Annual Sales (US$ Million), 2019-2023
Figure 7-18: Tasigna - Annual Sales by Region (US$ Million), 2022
Figure 7-19: Tasigna - Annual Sales by Region (%), 2022
Figure 7-20: Global - Tasigna Quarterly Sales (US$ Million), 2022
Figure 7-21: US - Tasigna Quarterly Sales (US$ Million), 2022
Figure 7-22: ROW - Tasigna Quarterly Sales (US$ Million), 2022
Figure 7-23: US - Tasigna Annual Sales (US$ Million), 2019-2023
Figure 7-24: ROW - Tasigna Annual Sales (US$ Million), 2019-2023
Figure 8-1: US - Bosulif Orphan Drug Designation Approval and Exclusivity for CML
Figure 8-2: Bosulif - Approval Year by Region
Figure 8-3: US - Bosulif Orphan Drug Designation and Approval Year
Figure 8-4: US - Bosulif Approval by Indication
Figure 8-5: US - Bosulif Patent Approval and Expiration Years
Figure 8-6: Europe - Bosulif EMA Approval and Patent Exclusivity Year
Figure 8-7: US - Cost of Supply of 120 Tablets and Per Unit Cost of Bosulif 100mg (US$), April’2023
Figure 8-8: US - Cost of Supply of 120 Tablets and Per Unit Cost of Bosulif 400mg and 500mg (US$), April’2023
Figure 8-9: UK - Cost of Supply of 28 Tablets and Per Unit Cost of Basulif 100mg (GBP/US$), April’2023
Figure 8-10: UK - Cost of Supply of 28 Tablets and Per Unit Cost of Bosulif 400mg and 500mg (GBP/US$), April’2023
Figure 8-11: Bosulif- Initial Recommended Dose by Indication for Adults (mg/day)
Figure 8-12: Bosulif- Minimum and Maximum Recommended Dose (mg/day)
Figure 8-13: Global - Bosulif Annual Sales (US$ Million), 2019-2023
Figure 8-14: US - Bosulif Annual Sales (US$ Million), 2019-2023
Figure 8-15: Europe - Bosulif Annual Sales (US$ Million), 2019-2023
Figure 8-16: Regional - Bosulif Quarterly Sales (US$ Million), Q1’2023
Figure 8-17: Regional - Bosulif Quarterly Sales (%), Q1’2023
Figure 8-18: Bosulif - Annual Sales by Region (US$ Million), 2022
Figure 8-19: Bosulif - Annual Sales by Region (%), 2022
Figure 8-20: Global - Bosulif Quarterly Sales (US$ Million), 2022
Figure 8-21: US - Bosulif Quarterly Sales (US$ Million), 2022
Figure 8-22: Europe - Bosulif Quarterly Sales (US$ Million), 2022
Figure 8-23: ROW - Bosulif Quarterly Sales (US$ Million), 2022
Figure 9-1: Iclusig - Orphan Drug Designation by Region
Figure 9-2: US - Iclusig Orphan Drug Designation and Approval Year
Figure 9-3: Europe - Iclusig Orphan Drug Designation and Approval Year
Figure 9-4: Iclusig - Approval Year by Region
Figure 9-5: US - Iclusig Approval by Indication
Figure 9-6: US - Iclusig Patent Approval and Expiration Year
Figure 9-7: Europe - Iclusig EMA Approval and Patent Exclusivity Year
Figure 9-8: Japan - Iclusig Approval and Patent Exclusivity Year
Figure 9-9: US - Cost of Supply of 30 Tablets and Per Unit Cost of Iclusig Oral Tablet (US$), April’2023
Figure 9-10: UK - Cost of Supply of 30 Tablets and Per Unit Cost of Iclusig 15mg (GBP/US$), April’2023
Figure 9-11: UK - Cost of Supply of 30 Tablets and Per Unit Cost of Iclusig 30mg and 45mg (GBP/US$), April’2023
Figure 9-12: Ponatinib - Initial and Dose Reductions for CP-CML (mg/day)
Figure 9-13: Ponatinib - Initial and Dose Reductions for Resistant CML and Ph+ ALL (mg/day)
Figure 9-14: Global - Iclusig Annual Sales (US$ Million), 2019-2023
Figure 9-15: Global - Iclusig Quarterly Sales (US$ Million), 2022
Figure 10-1: US - Scemblix Orphan Drug Designation and Approval Year
Figure 10-2: Scemblix - Approval Year by Region
Figure 10-3: US - Scemblix Patent Issue and Expiration Year
Figure 10-4: US - Scemblix FDA Approval and Patent Exclusivity Year
Figure 10-5: US - Cost of Supply of 60 Tablets and Per Unit Cost of Scemblix Oral Tablet (US$), April’2023
Figure 10-6: UK - Cost of Supply of 60 Tablets and Per Unit Cost of Scemblix Oral Tablet (US$), April’2023
Figure 10-7: Scemblix - Initial and Dose Reductions for Ph+ CML-CP, Previously Treated with Two or More TKIs (mg/day)
Figure 10-8: Scemblix - Initial and Dose Reductions for Ph+ CML-CP with the T315I Mutation (mg/day)
Figure 10-9: Global - Scemblix Quarterly Sales (US$ Million), 2022-2023
Figure 10-10: Global - Scemblix Quarterly Sales (US$ Million), 2022
Figure 10-11: US - Scemblix Quarterly Sales (US$ Million), 2022
Figure 10-12: ROW - Scemblix Quarterly Sales (US$ Million), 2022
Figure 10-13: Scemblix - Annual Sales by Region (%), 2022
Figure 11-1: China - Olverembatinib Priority Review, Breakthrough Therapy Designation and NMPA Approval Year
Figure 11-2: Olverembatinib - Orphan Designation by Region
Figure 11-3: Global - Olverembatinib Half-Yearly Sales (US$ Million), 2022
Figure 12-1: Global - Bcr Abl Inhibitor Drugs in Clinical Trials by Indication, 2023
Figure 12-2: Global - Bcr Abl Inhibitor Drugs in Clinical Trials by Company, 2023
Figure 12-3: Global - Bcr Abl Inhibitor Drugs in Clinical Trials by Country, 2023
Figure 12-4: Global - Bcr Abl Inhibitor Drugs in Clinical Trials by Patient Segment, 2023
Figure 12-5: Global - Bcr Abl Inhibitor Drugs in Clinical Trials by Phase, 2023
Figure 15-1: BCR-ABL Inhibitor Market Drivers
Figure 15-2: BCR-ABL Inhibitor Market Challenges
Table 1-1: Frequency of BCR-ABL Gene in Different Phenotypes of Leukemia
Table 15-1: BCR-ABL Inhibitors and Resistance Mechanisms